NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R61/R33 Clinical Trial Required)
The objective of this funding opportunity is to support investigator-initiated, Phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. In addition to supporting clinical trial start-up and im
About this program
The NHLBI Early Phase Clinical Trials grant supports innovative research aimed at developing new therapeutics and diagnostics for heart, lung, blood, and sleep disorders. This funding opportunity is designed for researchers who are conducting early phase clinical trials that can lead to significant advancements in the treatment and understanding of these critical health issues. The grant encourages collaboration among researchers and institutions to foster innovative approaches in the field. Eligible applicants include academic institutions, nonprofit organizations, and other research entities that have the capacity to conduct clinical trials. The grant aims to facilitate the transition of promising laboratory discoveries into clinical applications, ultimately improving patient outcomes. By providing financial support for these early-stage trials, the NHLBI seeks to accelerate the development of effective interventions for HLBS disorders.
Eligibility
Academic institutions, nonprofit organizations, and research entities capable of conducting clinical trials.